Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by StrikingMooseon Oct 30, 2017 2:21pm
93 Views
Post# 26877475

RE:Wallace still hard at work.

RE:Wallace still hard at work.Last message. My daughter is napping and I was excited to read it lol. My one line summary is that H2s is repeatedly demonstrating massive tissue protective effects in the stomach and intestines in all models studied. Especially evident when administered with an NSAID.

My takeaways from the article he just published (the october one) in the last confusing point form I can do

- H2s reduces inflammation (duh)
- H2S is produced by bacteria in the gut but exogenous H2S can also interact with existing gut biomes and some studies with very large exogenous doses of H2S has been surmised to maybe cause toxicity but has only shown proven DNA damage in cancer cells
- There has been some suggestion that H2S derived from bacteria in the gut can disrupt/alter the structure of mucus cells in the gut but has been proven by Wallace in lab with extensive rodent/dog testing (FYI dog testing is actually better than rodent because they are genetically more similar to humans than rodents.. doesn't state this in the article but it is a fact and studies are being done more commonly on dogs now with better linking of dog-human similar results than rodent-human results.. so seeing that Wallace at al have been testing on dogs too makes me very happy)
- In one test done by another researcher pediatrics with Crohns had intestinal damage when getting H2S donating drugs if they were part of a small group who had a genetic defect causing reduced H2S oxidation in their mitocondria
- Taking proton pump inhibitors (I take one.. interesting) caused worsening NSAID damage in the gut and also caused a LARGE increase in the type of bacteria that uses H2S in the gut (perhaps your body's way of trying to protect itself?)
- H2S in the gut repairs damage from alcohol, NSAID, colitis, ischemia. Damaged areas have markedly reduced H2S oxidation which make them even more vulnerable which is why H2S donating compounds help 

The first dozen pages or so was mostly a summary of H2S knowledge. Then they went into the meat of the paper regarding gut microbiome/mucus layer/defense from H2S. Background. Normally the gut has a layer of sterile mucus protecting the tissue from bacteria in the gut.

Bacteria - Mucus - Inner Tissues

like that.

They induced colitis in rodents and damaged the mucus layer and inhibited H2S synthesis in the gut itself (didn't give any extra H2S) and the mice that had H2S synthesis disrupted had much more bacterial penetration into the tissues and disorganized repair of its tissues. The mice with normal gut H2S synthesis was better. 

They then gave the same rodents an H2S donor delivered into the gut and saw massive repair and healing compared to the ones that didn't get H2S with the H2S receiving group having a fully restored sterile mucus layer.

He states how NSAID administration causes gut bacteria to shift from gram positive to gram negative which allows easier damage to the tissues. Giving an H2S donor greatly reduced the shift in gut bacteria which helped maintain gut health. It also helped to keep bile in a less toxic form helping further to reduce tissue damage.



Hope that helped. No need to read the full text now you won't gain anything really other than some numbers and a lot of useless medical jargon.
Bullboard Posts